Evidence map›Paper›PMID 33617094›Full record

ArticleExperimental dermatology2021

MTOR promotes basal cell carcinoma growth through atypical PKC.

Rachel Y Chow, Taylor M Levee, Gurleen Kaur, Daniel P Cedeno, Linda T Doan, Scott X Atwood

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Does Basal Cell Carcinoma Arise from a Precursor Lesion?The Journal of investigative dermatology · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rachel Y ChowDepartment of Developmental and Cell Biology, University of California, Irvine, CA, USA.
Taylor M LeveeDepartment of Developmental and Cell Biology, University of California, Irvine, CA, USA.
Gurleen KaurDepartment of Developmental and Cell Biology, University of California, Irvine, CA, USA.
Daniel P CedenoDepartment of Developmental and Cell Biology, University of California, Irvine, CA, USA.
Linda T DoanDepartment of Dermatology, University of California, Irvine, CA, USA.
Scott X AtwoodDepartment of Developmental and Cell Biology, University of California, Irvine, CA, USA.ORCID 0000-0001-7407-9792
University of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Phosphorylation-dependent regulation of GLI transcription factorsR01CA237563 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ATWOOD, SCOTT · 2019 to 2023
$1.7M
NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA237563
6 · The paper itself

Abstract

Advanced basal cell carcinomas (BCCs) are driven by the Hedgehog (HH) pathway and often possess inherent resistance to SMO inhibitors. Identifying and targeting pathways that bypass SMO could provide alternative treatments for patients with advanced or metastatic BCC. Here, we use a combination of RNA-sequencing analysis of advanced human BCC tumor-normal pairs and immunostaining of human and mouse BCC samples to identify an MTOR expression signature in BCC. Pharmacological inhibition of MTOR activity in BCC cells significantly reduces cell proliferation without affecting HH signalling. Similarly, treatment of the Ptch1

Indexed as

TOR Serine-Threonine KinasesAnimalsAntineoplastic AgentsBasal Cell CarcinomaCell Line, TumorCell ProliferationEverolimusHedgehog ProteinsHumansImidazolesImmunohistochemistryMicePatched-1 ReceptorProtein Kinase CSequence Analysis, RNASignal TransductionAntineoplastic AgentsEverolimusGli1 protein, mouseHedgehog ProteinsImidazolesMTOR protein, humanmTOR protein, mouseOSI 027Patched-1 ReceptorPKC-3 proteinProtein Kinase CPtch1 protein, mouseSirolimusTOR Serine-Threonine KinasesTriazinesZinc Finger Protein GLI1cancer heterogeneitycancer therapydrug resistanceHedgehog signallingSMO antagonist

Identifiers

PMID33617094
PMCPMC9924159
OpenAlexW3112760614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.